Cancer
Conditions
Interventions
experimental group:Di'ao Zihuangjing Tablets
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pathologically confirmed malignant tumor (solid tumor, excluding blood malignant tumor); 2. Patients whose clinical stage of tumor is IIIB-IV; 3. Patients who have received at least one cycle of chemotherapy and are expected to receive two or more cycles of chemotherapy of the same regimen in the future; the chemotherapy regimen takes 21 days as one cycle. 4. The score of cancer patients on the subjective fatigue level screening scale is >= 4 points. 5. Patients with normal cognitive function who can independently complete the questionnaire involved in the study; 6. Patients whose hematology, liver and kidney functions and important organ functions meet the requirements of chemotherapy; 7. Patients who have no obvious obstacle in swallowing function and can take the investigational drug smoothly; 8. Patients who know and agree to join the clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. The patients have other exact causes of fatigue (such as hypothyroidism, insomnia, uncontrolled pain, moderate to severe anemia, severe malnutrition, cachexia, etc.); 2. Patients who have been previously used or are allergic to Zihuangjing; 3. Patients who have been taking prescription stimulants or other drugs / health products clearly marked with anti fatigue effect; 4. Patients with symptomatic intracranial metastasis; 5. Patients with mental disorders (anxiety, manic depression, obsessive-compulsive disorder, schizophrenia), acute or chronic progressive or unstable nervous state (dementia, delirium or epilepsy), cognitive dysfunction; 6. Patients with other diseases requiring glucocorticoid treatment (excluding chemotherapy pretreatment); 7. Patients with poor compliance who are not expected to complete the study as planned; 8. Pregnant or lactating women; 9. Staff of the research center directly related to the test and / or their immediate family members.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Piper; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD3;CD4;albumin;Globulin;albumin/Globulin;Hb;EORTC QLQ C30;Adverse events; | — |
Countries
China
Contacts
Public ContactSun Yu
West China Hospital of Sichuan University
Outcome results
None listed